Discovery extended with quality, actionable data
High-throughput cell panel screening is a key drug development tool for identifying sensitive or resistant tumor types and genomic features governing response.
At Revvity, we have extensive experience in high-throughput phenotypic screening and drug profiling across large panels of cancer cell lines to provide efficacy and toxicity data for lead oncology therapeutics.
As an extension of your team, we can study drug response by identifying sensitive and resistant cells, aid patient stratification for drug candidates and combinations, and perform bioinformatics analysis that links molecular features with phenotypic response.
By working with our preclinical services team, you can benefit from:
- More than a decade of experience as a contract research organization – we’ve analyzed over 10 million unique drug combinations
- A cost-effective screening platform that delivers actionable insights in a short period of time
- Experience in screening of small molecules, biologics and ADCs
- Oncology-focused compound library of approved drugs, emerging therapeutics and molecular probes
- Customized treatment times and dosing regiments to more closely mirror in vivo studies
2D and 3D OncoSignature™ cell panel screening CRO services
Our CRO-style preclinical services provide cancer cell line panel screening with advanced 2D and 3D platforms to test the efficacy and antiproliferative effects to help streamline therapeutic pipelines and enhance patient stratification strategies. Working with us, you can leverage a broad cell line panel of 300 (2D) and 200 (3D) characterized cancer cell lines and analyze large screening datasets with the first results in one month.
Explore our cell panel screening services
Key Features
Learn about our services
2D OncoSignature cell panel screening services
Reveal the efficacy of your compounds or biologics as single agents or in combination
Across 300 cancer cell lines in just four months, the 2D OncoSignature drug discovery screening service can profile your compounds or biologics of interest as single or combination therapies.
Reveal the efficacy of your compounds or biologics as single agents or in combination
Across 300 cancer cell lines in just four months, the 2D OncoSignature drug discovery screening service can profile your compounds or biologics of interest as single or combination therapies.
2D OncoSignature cell panel screening applications:
- Study drug response by identifying sensitive and resistant cells
- Aid patient stratification for your drug candidate or drug combination
- Accelerate drug development by identifying drug combinations
Our 2D OncoSignature service includes:
- Screen across a diverse, clinically-relevant 300 cell line panel or a more focused, tissue-specific panel such as lung, lymphoma, head & neck, or breast
- Access to a library of over 350 standard-of-care compounds
- Cell lines grown in vendor-recommended media
- 10 point, 3-fold dilution for single compounds
- 9x9 full dose response matrix for compounds in combination
- 72, 96, 120, or 144 h treatment times
- Growth Inhibition measured by ATP levels
In your 2D OncoSignature report, you'll receive:
| Single agents |
|
| Combinations |
|
Understand more with the following resources:
2D OncoSignature HTRF™ assay services
Profile your compound of interest, as single or combination therapies, in our OncoSignature HTRF drug discovery screening service to gain broader insight into clinical efficacy
Leverage the capabilities of the OncoSignature platform, verified HTS workflow, and expert data analysis to equip you with quantitative data to help you elucidate underlying resistance and sensitivity mechanisms for more effective patient stratification.
Profile your compound of interest, as single or combination therapies, in our OncoSignature HTRF drug discovery screening service to gain broader insight into clinical efficacy
Leverage the capabilities of the OncoSignature platform, verified HTS workflow, and expert data analysis to equip you with quantitative data to help you elucidate underlying resistance and sensitivity mechanisms for more effective patient stratification.
Revvity’s HTRF assay technology allows for large-scale exploration of underlying cellular mechanisms of drug response across a broad, biologically relevant panel of cancer cell line models. We utilize this highly sensitive and robust TR-FRET technology to rapidly screen your lead agents in a fully automated cell panel screening platform to interrogate your target protein of interest. We provide you with robust quantitative data across a broad panel of cell lines for a comprehensive insight into drug efficacy, supporting you in making key decisions throughout your drug development process.
Key advantages of our 2D OncoSignature HTRF assay services:
- Access to a clinically relevant panel of our 300 OncoSignature cancer cell lines
- Verified workflow and screen design for high-throughput execution to help save you time and cost
- Over 350 HTRF assay kits available to study your target
- Continual screening cycle, flexible onboarding and compound submission
- Extensive in-house expertise
- Robust quantitative data and interpretation
Why use cell panel HTRF assay for drug discovery?
Understanding how and why different cancer types respond to therapy by studying the various molecular interactions and signaling pathways that underlie mechanisms of cancer development and progression is crucial for designing effective therapeutics. HTRF assays offer a way to study key disease processes, including GPCRs, kinases, epigenetics, protein-protein interactions and the quantification of a wide range of biomarkers and cytokines to help you understand your drug’s therapeutic effect.
Main applications of OncoSignature HTRF assay screening service:
- Correlate inhibitor responses with underlying pathway activation
- Confirm MOA and on-target activity of single agents and novel combinations
- Better understand factors driving sensitivity and resistance for more effective patient stratification
- Study drug effect on biomarkers associated with tumor growth and survival
Learn more about HTRF technology with the following resources:
Long-term cell panel screening with 2D OncoSignature assay
Profile slow-acting or epigenetic therapeutics over a prolonged period
Epigenetics offers the opportunity to identify new therapeutic targets for novel drug discovery and is a key area for cancer research.
Profile slow-acting or epigenetic therapeutics over a prolonged period
Epigenetics offers the opportunity to identify new therapeutic targets for novel drug discovery and is a key area for cancer research.
Epigenetic agents are typically studied using cellular assays and require longer time points to see their full effects. Conventional 3–6-day assay windows may not offer the resolution needed to identify or resolve the full cellular response. In addition, by using long-term assays in combination with other cancer therapies, such as chemotherapy, effectiveness can be improved. Our 2D OncoSignature Long-Term Assay drug discovery service profiles slower-acting drugs in 384-well plates for 10 days across a diverse, biologically relevant panel of 248 cell lines.
Our long-term assay service has been carefully designed by screening experts, and stringent controls have been applied to reduce potential variability and deliver reliable results in fast turnaround times. We test your agents in an optimized platform specifically designed for slower-acting agents and epigenetic targets to help identify potential therapeutics.
Key advantages of our long-term cell panel screening services:
- Fully automated high throughput screening platform.
- Continual screening cycle, flexible onboarding and compound submission.
- Fast turnaround times, 248 cell lines in 5 months.
- Dedicated project manager, simple project initiation with regular project updates and interim data.
- Detailed final report, raw data files.
- High quality data analysis, reliable and reproducible.
Applications of long-term assays:
- Study drug response by identifying sensitive and resistant cells at higher resolution.
- Aid patient stratification for your drug candidate or drug combination.
- Speed development of certain classes of long-acting drugs by identifying drug combinations over extended time points.
Learn more with the following resources:
3D OncoSignature cell panel screening services
Screen up to 200 cell lines from cell lines library grown in 3D spheroids
Our 3D oncology cell library can help to provide you with more physiologically relevant conditions to screen for a better understanding of candidate cancer therapeutics.
Screen up to 200 cell lines from cell lines library grown in 3D spheroids
Our 3D oncology cell library can help to provide you with more physiologically relevant conditions to screen for a better understanding of candidate cancer therapeutics.
Our 3D cell panel screening services include:
- Screen up to 40 single agents or 12 combinations (as a standard offering).
- Assessing cytotoxicity by metabolic-based readouts that measure ATP as an indicator of viability.
- Select standard or genetically modified cancer cell lines or send us your cell lines.
- Choose from a range of end-point assays.
- Expert bioinformatics analyses available as an optional add-in.
Consult with your dedicated project team to define project scope.
Learn more how Revvity can help your drug development with the following resources:
Combination Screening Services
Boost efficacy of lead compounds or overcome drug resistance mechanisms
Combination therapies can be an effective treatment option for many diseases, including cancer. By utilizing drug combinations, you can boost the efficacy of lead compounds or overcome drug resistance mechanisms.
Boost efficacy of lead compounds or overcome drug resistance mechanisms
Combination therapies can be an effective treatment option for many diseases, including cancer. By utilizing drug combinations, you can boost the efficacy of lead compounds or overcome drug resistance mechanisms.
With our combination screening services, we can screen large numbers of therapeutic agents to discover novel combination pairings that boost the therapeutic profile of a lead drug and enhance treatment outcomes.
Applications of combination screening:
- Study combination drug responses to identify synergistic and antagonistic interactions
- Compare drug activity with approved and emerging therapies
- Access over 800 highly characterised cell lines to rationalise patient stratification decisions for your drug candidate
- Study small molecules, antibodies, and antibody-drug conjugates
Our cancer cell line collection features:
- Over 800 cell lines, 90% of which overlap with Cancer Cell Line Encyclopedia (CCLE)
- Cell lines are characterized for their suitability for HTS work, including seeding densities and assay conditions to generate quality data
- Cell lines are grown in vendor-recommended media
Learn more how Revvity can help your drug development with the following resources:
High-Content Screening Services
HCS services for precise, multiplexed cellular insights in drug discovery
High-content screening (HCS) is an advanced imaging approach to screening that captures high-resolution cellular data to help provide deep biological insights. Using automation and multiplexed labeling, it enables the visualization of complex cellular processes and quantification of phenotypic changes.
HCS services for precise, multiplexed cellular insights in drug discovery
High-content screening (HCS) is an advanced imaging approach to screening that captures high-resolution cellular data to help provide deep biological insights. Using automation and multiplexed labeling, it enables the visualization of complex cellular processes and quantification of phenotypic changes.
At Revvity, our high-content screening (HCS) services are built on a foundation of extensive imaging and screening expertise, supported by a global network specializing in every aspect of the imaging workflow, including the development of the Opera Phenix Plus™ and Operetta CLS™ imagers, PhenoVue™ reagents, and Harmony™ and Signals™ software. This infrastructure and knowhow enable us to partner with our clients in a unique way to design and deliver high-content screens tailored to specific research needs.
Whether you want to explore how these cellular insights can advance your science, need additional capacity or expertise for a particular project, or are seeking a partner with ready-to-go cell models, our preclinical services team are well-placed to support you.
Cell health panel
Understanding cellular responses to genetic and chemical perturbations is essential for evaluating drug efficacy and toxicity. Our pre-optimized cell health panel assays provide a comprehensive, multiplexed approach to analyzing key cellular processes, including autophagy, apoptosis, DNA damage, and cell cycle dynamics.
Designed for seamless integration into our high-throughput screening (HTS) workflows, these pre-configured assay solutions support robust and efficient compound profiling, mechanism-of-action (MOA) analysis, and in-depth exploration of cellular health markers.
Custom HCS assay development services
We leverage over two decades of expertise in cellular imaging to deliver tailored high-content screening services for even complex drug discovery challenges. We work closely with clients to align with their needs, providing end-to-end support from custom assay development to the execution of screening campaigns.
Our clients benefit from:
- Access to our global team of cellular imaging experts for effective study design, troubleshooting, and data analysis
- Well-established platforms and significant expertise in a wide range of complex cell models and screen types, including cell panel screens, combination screens, functional genomic screens, and immune cell screens
- Pre-optimized cell health assays for seamless integration
- Custom assay development for specific screening needs
- Flexible small-scale or large-panel screening solutions
- Comprehensive high-throughput screening capabilities
Whether you need pre-optimized assays for rapid implementation or customized solutions for complex biological questions, Revvity’s high-content screening services provide precision, adaptability, and high-quality results to advance your drug discovery.
Learn more how Revvity can help your drug development with the following resources:
Focused cell panel screens
Accelerate targeted oncology discovery with focused cell panel screens
Curated panels aligned to key cancer drivers, from RAS mutations to DDR deficiencies, to help you profile compounds, validate mechanisms, and generate high-confidence data, faster.
Accelerate targeted oncology discovery with focused cell panel screens
Curated panels aligned to key cancer drivers, from RAS mutations to DDR deficiencies, to help you profile compounds, validate mechanisms, and generate high-confidence data, faster.
Why choose a focused cell panel
When investigating a specific pathway or cancer type, testing compounds in a panel curated for biological relevance offers clearer, faster answers. Focused panels are built around the most therapeutically important mutations, resistance mechanisms, and tumor contexts, allowing you to observe pathway-specific drug responses without the noise of unrelated models. Instead of spending time selecting and verifying cell lines, you can start with a ready-to-use, well-annotated panel aligned with your research goals. This speeds up project initiation, reduces internal resource burden, and allows you to focus on generating quality data from day one. Whether you're profiling a KRAS inhibitor, a DDR-targeting agent, or exploring tumor-specific vulnerabilities, focused screening allows you to move faster, and with greater confidence in what your data is telling you.
Our focused panels
Pathway-driven panels
- RAS Panel: KRAS, NRAS, and HRAS mutant models across lung, pancreatic, and hematologic cancers for targeted inhibitor profiling.
- EGFR Panel: NSCLC models with EGFR activating mutations, resistance variants, and wild-type comparators.
- DNA Damage Response (DDR) Panel: Models with BRCA1/2, ATM, ATR, CHK1/2, and other DDR gene alterations to support PARP inhibitor profiling and synthetic lethality studies.
Tissue-specific panels
- Lung Cancer Panel: NSCLC and SCLC models with EGFR, KRAS, ALK, and MET aberrations representative of key clinical subtypes.
- Hematologic Malignancies Panel: AML, ALL, and lymphoma models with FLT3-ITD, IDH1/2, BCL2, JAK2, and other relevant drivers.
- Breast & Ovarian Cancer Panel: Hormone receptor-positive, HER2-amplified, triple-negative, and BRCA-deficient models for mechanism-driven screening.
- Prostate Cancer Panel: Models representing AR-driven, castration-resistant, and neuroendocrine subtypes, with PTEN, TP53, and SPOP mutations.
- Endometrial Cancer Panel: Diverse histologic and molecular subtypes, including models with PI3K pathway alterations and mismatch repair deficiencies.
Why Revvity
- Built on our established OncoSignature™ platform for viability and high-content phenotypic screening
- Accelerated timelines with screening runs offered quarterly
- Typical turnaround time: 8–10 weeks
- Standard-of-care (SOC) benchmark data included for comparative insight
- Attractive pricing for both early discovery and pipeline-stage programs
- Curated genomic and phenotypic annotations to support data interpretation
- Data generated across 2D, 3D, and biologics-compatible assay formats
Learn more how Revvity can help your drug development with the following resources:
Custom cell-based screen projects
Partner with our experts to overcome your challenges
Are you facing the problem of limited resources or expertise to tackle complex screen projects? Consult with our dedicated project team to define project scope, timelines, and goals.
Partner with our experts to overcome your challenges
Are you facing the problem of limited resources or expertise to tackle complex screen projects? Consult with our dedicated project team to define project scope, timelines, and goals.
When you work with us, you’ll receive frequent and regular status updates, so you’re informed about your project's progress, milestones, and significant developments, enabling you to make informed decisions and provide timely feedback.
You’ll be provided with a comprehensive and in-depth analysis of results, delivered with our commitment to reliable data. Our rigorous analytical methods deliver accurate and meaningful interpretations, empowering you to make data-driven decisions and drive future strategies.
Benefits of outsourcing your cell panel screening with us include:
- Increased efficiency and time savings: Focus on core competencies while we handle specialized and time-consuming tasks.
- Specialized access: Leverage our global talent pool for diverse skills and expertise.
- Scalability and flexibility: Easily adjust operations to match your business needs.
- Risk management: Share risks with us to lower your burden.
- Comprehensive project management: A dedicated team provides clear project scopes, timelines, regular updates, and in-depth result analysis.
Advanced capabilities
- Miniaturized cell assays and imaging analytics: Includes protein readouts such as HTRF, AlphaLISA™, and BioLegend LEGENDplex™.
- Extensive screening options: Access 650+ cancer cell lines, 4000+ mutant and wild-type pairs, and 350+ standard-of-care drugs. Choose from dose matrices, assay endpoints, drug sequencing, and environmental conditions in 2D or 3D models.
- Enhanced and pairwise screening: Identify selective enhancers, novel synergistic drug combinations, and molecular features responsive to your therapies.
Contact us today to book a consultation with our expert team to discuss how we can help accelerate your research projects.
Learn more how Revvity can help your drug development with the following resources:
